SGLT2 inhibitors are promising new therapies for MAFLD and other cardiovascular diseases such as congestive heart failure; however, it is unclear if they have a direct effect on hepatic steatosis or work through effects on body weight and insulin sensitivity. Here, INS is linked to fatty liver disease.